Login
E-mail
Password
Mostra password
Ricorda
Password dimenticata?
Iscriviti gratuitamente
Registrazione
Registrazione
Parametri
Parametri
Quotazioni dinamiche 
OFFON

YUMANITY THERAPEUTICS, INC.

(YMTX)
Prezzo stimato in tempo reale. Tempo reale stimato Cboe BZX - 26/10 17:55:31
9.06 USD   +0.22%
04/06YUMANITY THERAPEUTICS, INC.: da HC Wainwright è Buy
MM
01/04YUMANITY THERAPEUTICS, INC.: Jefferies & Co. ancora positivo
MM
RiassuntoQuotazioniGraficiNotizieRatingAgendaSocietąFinanzaConsensusRevisioniDerivati 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su YUMANITY THERAPEUTICS, INC.
14/10Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/09YUMANITY THERAPEUTICS: Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09/09YUMANITY THERAPEUTICS: to Present at the H.C. Wainwright 23rd Global Investment Conferenc..
16/08Yumanity Therapeutics, Inc. Announces Appointment of Michael D. Wyzga as Chief Financia..
16/08YUMANITY THERAPEUTICS: Appoints Michael D. Wyzga as Chief Financial Officer and Announces..
16/08YUMANITY THERAPEUTICS, INC.: Change in Directors or Principal Officers, Regulation FD Dis..
16/08Yumanity Therapeutics, Inc. Announces Executive Changes
16/08Yumanity Therapeutics Appoints Michael D. Wyzga as Chief Financial Officer and Announce..
13/08YUMANITY: Q2 Earnings Snapshot
12/08YUMANITY THERAPEUTICS: Reports Second Quarter 2021 Financial Results and Recent Corporate..
12/08YUMANITY THERAPEUTICS: Management's Discussion and Analysis of Financial Condition and Re..
12/08YUMANITY THERAPEUTICS, INC.: Results of Operations and Financial Condition, Financial Sta..
12/08Yumanity Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June ..
12/08YUMANITY THERAPEUTICS: Earnings Flash (YMTX) YUMANITY THERAPEUTICS Posts Q2 Revenue $2.11..
12/08Yumanity Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporat..
12/08Yumanity Therapeutics Announces Management Changes
06/08YUMANITY THERAPEUTICS: to Present at the BTIG Virtual Biotechnology Conference
16/06YUMANITY THERAPEUTICS, INC.: Regulation FD Disclosure, Financial Statements and Exhibits ..
14/06Yumanity Therapeutics Appoints Devin W. Smith as General Counsel
14/06Yumanity Therapeutics Announces Appointment of Devin W. Smith as Senior Vice President ..
07/06YUMANITY THERAPEUTICS, INC.: Change in Directors or Principal Officers, Submission of Mat..
07/06N. Anthony Coles Transitions to the Role of Non-Executive Chair of the Board of Directo..
27/05Yumanity Therapeutics to Present at Upcoming Virtual Investor Conferences
17/05YUMANITY THERAPEUTICS, INC.: Regulation FD Disclosure, Financial Statements and Exhibits ..
17/05Yumanity Therapeutics' R&D Day Reviews Near-Term Value Drivers and Pipeline-Generating ..
13/05YUMANITY THERAPEUTICS: Management's Discussion and Analysis of Financial Condition and Re..
13/05YUMANITY THERAPEUTICS, INC.: Results of Operations and Financial Condition, Financial Sta..
13/05Yumanity Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the F..
13/05YUMANITY: Q1 Earnings Snapshot
13/05YUMANITY THERAPEUTICS: Earnings Flash (YMTX) YUMANITY THERAPEUTICS Posts Q1 Revenue $3.5M
13/05YUMANITY THERAPEUTICS: Reports First Quarter 2021 Financial Results and Recent Corporate ..
12/05YUMANITY THERAPEUTICS: to Present at the 2021 RBC Capital Markets Global Healthcare Confe..
04/05YUMANITY THERAPEUTICS: to Host Virtual R&D Day on Monday, May 17, 2021
29/04Yumanity Therapeutics to Present at the 2021 B. Riley Securities' Neuroscience Conferen..
22/04YUMANITY THERAPEUTICS, INC.: Other Events, Financial Statements and Exhibits (form 8-K)
22/04Yumanity Therapeutics' YTX-7739 Achieved Target Engagement at Doses That Were Generally..
22/04Yumanity Therapeutics’ YTX-7739 Achieves Target Engagement At Doses in Phase 1A Multipl..
13/04YUMANITY THERAPEUTICS: Appoints Neuroscience Drug Development Veteran, Ajay Verma, M.D., ..
13/04Yumanity Therapeutics Appoints Ajay Verma as Executive Vice President and Head of Resea..
08/04YUMANITY THERAPEUTICS, INC.: Entry into a Material Definitive Agreement, Termination of a..
08/04YUMANITY THERAPEUTICS: Financial Statements and Exhibits (form 8-K/A)
06/04YUMANITY THERAPEUTICS: YTX-7739 Trial Shows Efficacy in Glioblastoma Multiforme Mouse Mod..
06/04Yumanity Therapeutics Announces Study Demonstrating In Vivo Efficacy of YTX-7739 in a G..
06/04Yumanity Therapeutics Announces Study Demonstrating in Vivo Efficacy of YTX-7739 in a G..
31/03YUMANITY THERAPEUTICS: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE..
31/03YUMANITY THERAPEUTICS, INC.: Results of Operations and Financial Condition, Financial Sta..
31/03Yumanity Therapeutics, Inc. Reports Earnings Results for the Year Ended December 31, 20..
31/03Yumanity Therapeutics Reports Full Year 2020 Financial Results and Recent Corporate Dev..
09/03YUMANITY THERAPEUTICS: Reports Results of Study into Potential Parkinson Disease Therapy
09/03YUMANITY THERAPEUTICS: rsquo; YTX-7739 Demonstrates Prevention of Motor Function Deficits..
09/03Yumanity Therapeutics’ Ytx-7739 Demonstrates Prevention of Motor Function Deficits in A..
02/03YUMANITY THERAPEUTICS: to Present at the H.C. Wainwright Global Life Sciences Conference
02/03Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
10/02YUMANITY THERAPEUTICS: Initiates Dosing in Phase 1B Study in Parkinson's Disease Trial
10/02YUMANITY THERAPEUTICS, INC.: Other Events, Financial Statements and Exhibits (form 8-K)
10/02YUMANITY THERAPEUTICS: Provides Update on Its Lead Parkinson's Disease Clinical Program, ..
10/02Yumanity Therapeutics Provides Update on its Lead Parkinson’s Disease Clinical Program,..
04/02YUMANITY THERAPEUTICS: Files Shelf of Up to About 1.5 Million Common Shares on Behalf of ..
03/02YUMANITY THERAPEUTICS: Other Events, Financial Statements and Exhibits (form 8-K/A)
11/01YUMANITY THERAPEUTICS, INC.: Regulation FD Disclosure, Financial Statements and Exhibits ..
06/01YUMANITY THERAPEUTICS: to Present at the H.C. Wainwright Virtual BioConnect Conference
2020YUMANITY THERAPEUTICS, INC.(NASDAQCM: YMTX) added to NASDAQ Composite Index
2020YUMANITY THERAPEUTICS: Proteostasis Therapeutics Complete Merger
2020YUMANITY THERAPEUTICS: Proteostasis Shareholders OK Yumanity Merger Deal
2020Yumanity Therapeutics, Inc. announced that it has received $33.599992 million in fundin..
2020Yumanity Therapeutics Inc. announced that it expects to receive $33.599992 million in f..
2020Yumanity Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
2020Yumanity Therapeutics Announces Board Appointments
2020Yumanity Therapeutics Inc. Appoints Richard Peters as Chief Executive Officer
2020Yumanity Therapeutics Appoints Ellen K. Forest as Chief Human Resources Officer
2019Yumanity Therapeutics Inc. Appoints Brigitte Robertson as Chief Medical Officer
2019Yumanity Therapeutics Names Patricia Allen to Its Board
2019Yumanity Therapeutics Inc. Appoints Patricia Allen to its Board of Directors and Chairp..
2019Yumanity Therapeutics Announces Management Changes, Effective September 3, 2019
2018Yumanity Therapeutics Announces Publication of Paper in Cell Reports Detailing a Potent..
1  2Pross.